David Fajgenbaum
#123,129
Most Influential Person Now
American immunologist
David Fajgenbaum's AcademicInfluence.com Rankings
David Fajgenbaumbiology Degrees
Biology
#15194
World Rank
#19121
Historical Rank
Immunology
#1064
World Rank
#1090
Historical Rank
Download Badge
Biology
David Fajgenbaum's Degrees
- Bachelors Biology Georgetown University
- Doctorate Medicine University of Pennsylvania
- Masters Business Administration University of Pennsylvania
- Masters Translational Medicine University of Pennsylvania
Similar Degrees You Can Earn
Why Is David Fajgenbaum Influential?
(Suggest an Edit or Addition)According to Wikipedia, David C. Fajgenbaum is an American immunologist and author who is currently an assistant professor at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research into Castleman disease.
David Fajgenbaum's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cytokine Storm (2020) (565)
- International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. (2017) (320)
- HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. (2014) (260)
- Idiopathic multicentric Castleman's disease: a systematic literature review. (2016) (197)
- Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman disease (2016) (183)
- International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. (2018) (179)
- Overview of Castleman Disease. (2020) (145)
- Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. (2017) (116)
- The full spectrum of Castleman disease: 273 patients studied over 20 years (2018) (113)
- Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. (2018) (71)
- Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. (2019) (66)
- International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. (2020) (59)
- Castleman Disease Pathogenesis. (2018) (59)
- Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease (2018) (49)
- Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review (2020) (46)
- Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. (2013) (44)
- The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. (2016) (38)
- Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate (2021) (36)
- Teaching Old Drugs New Tricks: Statins for COVID-19? (2020) (33)
- Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. (2019) (31)
- Predictors of response to anti‐IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data (2018) (29)
- TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature (2017) (29)
- Increased mTOR activation in idiopathic multicentric Castleman disease. (2020) (28)
- Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference (2018) (27)
- Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. (2020) (26)
- TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. (2017) (21)
- Castleman disease (2019) (21)
- Building a Network of Grief Support on College Campuses: A National Grassroots Initiative (2012) (20)
- Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease (2021) (20)
- Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review (2019) (19)
- Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease (2019) (19)
- Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. (2016) (18)
- Validated International Definition of the TAFRO clinical subtype of idiopathic multicentric Castleman disease. (2021) (17)
- ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder (2020) (16)
- Increased mTOR activation in idiopathic multicentric Castleman disease (2019) (16)
- Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease (2020) (16)
- Emerging role of 18F-FDG PET/CT in Castleman disease: a review (2021) (14)
- Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease (2018) (13)
- DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells (2021) (11)
- A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. (2018) (11)
- Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. (2021) (11)
- HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review (2014) (10)
- Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy (2021) (10)
- Genetic basis for iMCD-TAFRO (2020) (9)
- Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. (2018) (9)
- Transcriptome and unique cytokine microenvironment of Castleman disease (2021) (8)
- Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome (2017) (8)
- Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research (2015) (8)
- Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. (2018) (7)
- Symptomatic relapse and long-term sequelae of COVID-19 in a previously healthy 30-year-old man (2020) (7)
- Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach (2017) (6)
- UCD with MCD-like inflammatory state: surgical excision is highly effective. (2021) (6)
- into biology, pathogenesis, and therapy HHV-8-negative, idiopathic multicentric Castleman disease: novel insights (2014) (6)
- A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD (2022) (6)
- HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. (2020) (5)
- Cytokine Storm. Reply. (2021) (4)
- Adrenalitis and anasarca in idiopathic multicentric Castleman's disease (2021) (4)
- Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes (2017) (4)
- Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease (2017) (4)
- Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease (2021) (4)
- The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases. (2019) (4)
- AA amyloidosis associated with Castleman disease (2020) (3)
- Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine (2022) (3)
- Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review (2022) (3)
- Sharing is caring: a call for a new era of rare disease research and development (2022) (2)
- Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses (2017) (2)
- Anti-type I interferon antibodies as a cause of severe COVID-19. (2022) (2)
- College Student Bereavement: University Responses, Programs and Policies, and Recommendations for Improvement (2007) (2)
- TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy (2021) (2)
- Treatment of Castleman Disease (2015) (2)
- Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain (2019) (2)
- Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells Reveals Changes in Immune Cell Composition and Distinct Inflammatory Gene Expression Profiles during Idiopathic Multicentric Castleman Disease Flare (2018) (2)
- Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease (2021) (2)
- Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease (2021) (2)
- insights into biology, pathogenesis, and therapy HHV-8-negative, idiopathic multicentric Castleman disease: novel (2014) (2)
- Oligoclonal Expansion of Cd8+ T Cells during Idiopathic Multicentric Castleman Disease Flares Suggests an Antigen Driven Process (2018) (1)
- Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare (2019) (1)
- Thrombocytopenia, anasarca, and severe inflammation (2022) (1)
- Living Life Laser-Focused: A Young Man Forced To Be Both Doctor and Patient. (2015) (1)
- Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines (2022) (1)
- Treatments administered to the first 9,152 reported cases of COVID19: a systematic review (2020) (1)
- The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease (2022) (1)
- A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria (2023) (1)
- Quantitative analysis of a rare disease network’s international contact database and E-repository provides insights into biobanking in the electronic consent era (2019) (1)
- Castleman disease spectrum. (2020) (1)
- Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease (2018) (1)
- Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease (2019) (1)
- Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis. (2022) (1)
- A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients (2020) (1)
- Letter to the editor regarding ‘Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report’ (2019) (1)
- Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease. (2021) (1)
- The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry (2022) (1)
- Increased mTORC2 Pathway Activation in Lymph Nodes of Imcd-Tafro (2021) (1)
- P-030: Bone marrow findings of Idiopathic Multicentric Castleman Disease: a histopathologic analysis and systematic literature review (2021) (1)
- A case report and review of the literature (2000) (0)
- A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases (2023) (0)
- Assessment of vitamin D deficiency and COVID-19 diagnosis in patients with breast or prostate cancer using electronic medical records. (2021) (0)
- A novel cryopreservation and biobanking strategy to study lymphoid tissue stromal cells in human disease (2023) (0)
- Serum Proteomics Identifies Interferon Gamma Signaling in Idiopathic Multicentric Castleman Disease (2022) (0)
- P-121: Healthcare resource utilization and morbidities in patients with idiopathic Multicentric Castleman Disease (2021) (0)
- Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies (2022) (0)
- A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (0)
- Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease (2022) (0)
- Special Report International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease (2019) (0)
- Ongoing Symptoms and Reduced Health Measures in Unicentric Castleman Disease Patients Despite Perceived-to-be Curative Surgical Excision (2021) (0)
- Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients (2018) (0)
- Red Blood Cell Morphological Changes and Enlarged Platelets Found in Idiopathic Multicentric Castleman Disease (2021) (0)
- A Rare Disease That Picked the Wrong Family: Fighting Back to Help a Loved One and as a Tool for Actively Coping (2015) (0)
- P1733: NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET (2022) (0)
- Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. Reply. (2022) (0)
- Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis (2022) (0)
- P-122: Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO (2021) (0)
- Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass. (2022) (0)
- Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry (2022) (0)
- A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders (2022) (0)
- EPR22-107: Evaluation of Early Risk of Moderate-to-Severe Cytokine Release Syndrome (CRS) Induced by CAR T-cell Therapy Using Pooled Clinical Trial Data (2022) (0)
- Increased mTORC2 pathway activation in lymph nodes of iMCD‐TAFRO (2022) (0)
- Emerging morbidities and health care resource utilization in idiopathic multicentric Castleman disease patients: A population-level analysis using health claims-based dataset. (2022) (0)
- Leveraging information and collaboration to cure disease (2017) (0)
- Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease (2021) (0)
- Publisher Correction: Back to the future with machine learning (2021) (0)
- Acknowledgement to Referees (2005) (0)
- Back to the future with machine learning (2021) (0)
- PS1403 IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) IN EUROPE: A HETEROGENEOUS DISEASE TREATED WITH A VARIETY OF AGENTS (2019) (0)
- Rare disease research requires (and benefits from) global collaboration: three examples from the Castleman Disease Collaborative Network (2016) (0)
- CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease (2022) (0)
- Correction to: Sharing is caring: a call for a new era of rare disease research and development (2023) (0)
- Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis (2022) (0)
- A Type I interferon response is associated with increased mTOR activation in idiopathic multicentric Castleman disease (2020) (0)
- Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia. (2020) (0)
- Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis (2022) (0)
- Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease (2022) (0)
- Characterizing Serum Cytokine Levels in Idiopathic Multicentric Castleman Disease Reveals Increased Chemokines and a Potential Signature Compared to Related Diseases (2021) (0)
- Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity (2021) (0)
- Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: reply. (2020) (0)
- Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling (2022) (0)
- We Get It (2015) (0)
- Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy (2022) (0)
- Unicentric Castleman disease-UpToDate (2019) (0)
- Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome (2018) (0)
- P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (2022) (0)
This paper list is powered by the following services:
Other Resources About David Fajgenbaum
What Schools Are Affiliated With David Fajgenbaum?
David Fajgenbaum is affiliated with the following schools:
